Chardan Capital analyst Keay Nakae reiterated a Buy rating on Caladrius Biosciences (CLBS) today and set a price target of $6. The company’s shares closed last Monday at $2.66, close to its 52-week low of $2.16.
According to TipRanks.com, Nakae has currently no stars on a ranking scale of 0-5 stars, with an average return of -11.0% and a 33.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Emergent Biosolutions.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caladrius Biosciences with a $10.42 average price target, a 296.2% upside from current levels. In a report issued on August 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.50 price target.
See today’s analyst top recommended stocks >>
Based on Caladrius Biosciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $5.14 million. In comparison, last year the company had a GAAP net loss of $4.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03.
